LifeMD (NASDAQ:LFMD) Given New $6.00 Price Target at HC Wainwright

LifeMD (NASDAQ:LFMD – Get Free Report) had its price objective lowered by stock analysts at HC Wainwright from $9.00 to $6.00 in a research report issued on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright‘s price objective would suggest a potential upside of 234.26% from the stock’s current price.

Several other equities analysts also recently weighed in on LFMD. Mizuho dropped their price target on LifeMD from $7.00 to $6.00 and set an “outperform” rating for the company in a research report on Friday, November 13th. Weiss Ratings reissued a “sell (d)” rating on shares of LifeMD in a research note on Monday, November 2nd. Lake Street Capital reduced their target price on shares of LifeMD from $5.00 to $3.00 and set a “buy” rating on the stock in a report on Friday, November 13th. Zacks Research raised shares of LifeMD from a “strong sell” rating to a “hold” rating in a research note on Monday, August 17th. Finally, BTIG Research lowered their price target on shares of LifeMD from $10.00 to $9.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $6.71.

Get Our Latest Stock Analysis on LifeMD

LifeMD Price Performance

Shares of LFMD opened at $1.79 on Wednesday. The firm has a 50 day simple moving average of $2.55 and a 200-day simple moving average of $3.56. LifeMD has a 1-year low of $1.60 and a 1-year high of $5.38. The stock has a market cap of $86.75 million, a price-to-earnings ratio of -29.92 and a beta of 2.19.

LifeMD (NASDAQ:LFMD – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.03. LifeMD had a negative return on equity of 188.63% and a negative net margin of 0.25%. The firm had revenue of $44.63 million during the quarter, compared to the consensus estimate of $48.84 million. On average, equities analysts expect that LifeMD will post -0.48 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. grew its stake in LifeMD by 8.0% during the second quarter. BlackRock Inc. now owns 3,034,535 shares of the company’s stock worth $12,533,000 after buying an additional 225,510 shares during the period. State Street Corp increased its position in shares of LifeMD by 22.6% in the second quarter. State Street Corp now owns 1,318,784 shares of the company’s stock worth $5,447,000 after acquiring an additional 243,376 shares in the last quarter. Marshall Wace LLP increased its position in shares of LifeMD by 45.1% in the third quarter. Marshall Wace LLP now owns 809,138 shares of the company’s stock worth $2,347,000 after acquiring an additional 251,664 shares in the last quarter. Walleye Capital LLC acquired a new stake in shares of LifeMD in the second quarter worth $1,338,000. Finally, Russell Investments Group Ltd. raised its stake in shares of LifeMD by 5,801.2% in the 2nd quarter. Russell Investments Group Ltd. now owns 314,770 shares of the company’s stock valued at $1,300,000 after acquiring an additional 309,436 shares during the period. 35.52% of the stock is owned by institutional investors and hedge funds.

LifeMD Company Profile

(Get Free Report)

LifeMD, Inc. is a virtual healthcare company that connects patients with medical providers through its telehealth platform. Its services include virtual primary care and specialty care, with offerings in areas such as men’s health and weight management. The company operates the LifeMD and Rex MD brands and supports care through online consultations, treatment plans and, when prescribed, medication. Service availability and treatment options may vary by state and individual patient needs. LifeMD serves patients in the United States.

Read More

Analyst Recommendations for LifeMD (NASDAQ:LFMD)

Receive News & Ratings for LifeMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeMD and related companies with MarketBeat.com's FREE daily email newsletter.